Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320483202> ?p ?o ?g. }
- W4320483202 endingPage "227" @default.
- W4320483202 startingPage "213" @default.
- W4320483202 abstract "Temporary drug treatment cessation might alleviate toxicity without substantially compromising efficacy in patients with cancer. We aimed to determine if a tyrosine kinase inhibitor drug-free interval strategy was non-inferior to a conventional continuation strategy for first-line treatment of advanced clear cell renal cell carcinoma.This open-label, non-inferiority, randomised, controlled, phase 2/3 trial was done at 60 hospital sites in the UK. Eligible patients (aged ≥18 years) had histologically confirmed clear cell renal cell carcinoma, inoperable loco-regional or metastatic disease, no previous systemic therapy for advanced disease, uni-dimensionally assessed Response Evaluation Criteria in Solid Tumours-defined measurable disease, and an Eastern Cooperative Oncology Group performance status of 0-1. Patients were randomly assigned (1:1) at baseline to a conventional continuation strategy or drug-free interval strategy using a central computer-generated minimisation programme incorporating a random element. Stratification factors were Memorial Sloan Kettering Cancer Center prognostic group risk factor, sex, trial site, age, disease status, tyrosine kinase inhibitor, and previous nephrectomy. All patients received standard dosing schedules of oral sunitinib (50 mg per day) or oral pazopanib (800 mg per day) for 24 weeks before moving into their randomly allocated group. Patients allocated to the drug-free interval strategy group then had a treatment break until disease progression, when treatment was re-instated. Patients in the conventional continuation strategy group continued treatment. Patients, treating clinicians, and the study team were aware of treatment allocation. The co-primary endpoints were overall survival and quality-adjusted life-years (QALYs); non-inferiority was shown if the lower limit of the two-sided 95% CI for the overall survival hazard ratio (HR) was 0·812 or higher and if the lower limit of the two-sided 95% CI of the marginal difference in mean QALYs was -0·156 or higher. The co-primary endpoints were assessed in the intention-to-treat (ITT) population, which included all randomly assigned patients, and the per-protocol population, which excluded patients in the ITT population with major protocol violations and who did not begin their randomisation allocation as per the protocol. Non-inferiority was to be concluded if it was met for both endpoints in both analysis populations. Safety was assessed in all participants who received a tyrosine kinase inhibitor. The trial was registered with ISRCTN, 06473203, and EudraCT, 2011-001098-16.Between Jan 13, 2012, and Sept 12, 2017, 2197 patients were screened for eligibility, of whom 920 were randomly assigned to the conventional continuation strategy (n=461) or the drug-free interval strategy (n=459; 668 [73%] male and 251 [27%] female; 885 [96%] White and 23 [3%] non-White). The median follow-up time was 58 months (IQR 46-73 months) in the ITT population and 58 months (46-72) in the per-protocol population. 488 patients continued on the trial after week 24. For overall survival, non-inferiority was demonstrated in the ITT population only (adjusted HR 0·97 [95% CI 0·83 to 1·12] in the ITT population; 0·94 [0·80 to 1·09] in the per-protocol population). Non-inferiority was demonstrated for QALYs in the ITT population (n=919) and per-protocol (n=871) population (marginal effect difference 0·06 [95% CI -0·11 to 0·23] for the ITT population; 0·04 [-0·14 to 0·21] for the per-protocol population). The most common grade 3 or worse adverse events were hypertension (124 [26%] of 485 patients in the conventional continuation strategy group vs 127 [29%] of 431 patients in the drug-free interval strategy group); hepatotoxicity (55 [11%] vs 48 [11%]); and fatigue (39 [8%] vs 63 [15%]). 192 (21%) of 920 participants had a serious adverse reaction. 12 treatment-related deaths were reported (three patients in the conventional continuation strategy group; nine patients in the drug-free interval strategy group) due to vascular (n=3), cardiac (n=3), hepatobiliary (n=3), gastrointestinal (n=1), or nervous system (n=1) disorders, and from infections and infestations (n=1).Overall, non-inferiority between groups could not be concluded. However, there seemed to be no clinically meaningful reduction in life expectancy between the drug-free interval strategy and conventional continuation strategy groups and treatment breaks might be a feasible and cost-effective option with lifestyle benefits for patients during tyrosine kinase inhibitor therapy in patients with renal cell carcinoma.UK National Institute for Health and Care Research." @default.
- W4320483202 created "2023-02-14" @default.
- W4320483202 creator A5000771821 @default.
- W4320483202 creator A5002598093 @default.
- W4320483202 creator A5002802780 @default.
- W4320483202 creator A5004849378 @default.
- W4320483202 creator A5006273372 @default.
- W4320483202 creator A5008424225 @default.
- W4320483202 creator A5009861042 @default.
- W4320483202 creator A5009975766 @default.
- W4320483202 creator A5010277875 @default.
- W4320483202 creator A5010355591 @default.
- W4320483202 creator A5010936863 @default.
- W4320483202 creator A5011164681 @default.
- W4320483202 creator A5011233738 @default.
- W4320483202 creator A5011478183 @default.
- W4320483202 creator A5013298540 @default.
- W4320483202 creator A5014640093 @default.
- W4320483202 creator A5016327424 @default.
- W4320483202 creator A5016906309 @default.
- W4320483202 creator A5017165070 @default.
- W4320483202 creator A5017669437 @default.
- W4320483202 creator A5018971091 @default.
- W4320483202 creator A5022329395 @default.
- W4320483202 creator A5023608008 @default.
- W4320483202 creator A5024531247 @default.
- W4320483202 creator A5024897723 @default.
- W4320483202 creator A5025402084 @default.
- W4320483202 creator A5026680419 @default.
- W4320483202 creator A5026817748 @default.
- W4320483202 creator A5026944178 @default.
- W4320483202 creator A5029517329 @default.
- W4320483202 creator A5029876655 @default.
- W4320483202 creator A5029986829 @default.
- W4320483202 creator A5030406466 @default.
- W4320483202 creator A5030506806 @default.
- W4320483202 creator A5030946586 @default.
- W4320483202 creator A5031016694 @default.
- W4320483202 creator A5032855339 @default.
- W4320483202 creator A5033550661 @default.
- W4320483202 creator A5034005852 @default.
- W4320483202 creator A5035187235 @default.
- W4320483202 creator A5035679710 @default.
- W4320483202 creator A5036443989 @default.
- W4320483202 creator A5036683194 @default.
- W4320483202 creator A5037342439 @default.
- W4320483202 creator A5037937397 @default.
- W4320483202 creator A5037978088 @default.
- W4320483202 creator A5039093518 @default.
- W4320483202 creator A5039227106 @default.
- W4320483202 creator A5039368541 @default.
- W4320483202 creator A5039402351 @default.
- W4320483202 creator A5040732176 @default.
- W4320483202 creator A5040908788 @default.
- W4320483202 creator A5040963787 @default.
- W4320483202 creator A5043445659 @default.
- W4320483202 creator A5045950154 @default.
- W4320483202 creator A5046999320 @default.
- W4320483202 creator A5048669460 @default.
- W4320483202 creator A5048796030 @default.
- W4320483202 creator A5049951818 @default.
- W4320483202 creator A5049996683 @default.
- W4320483202 creator A5052950047 @default.
- W4320483202 creator A5054713131 @default.
- W4320483202 creator A5054724709 @default.
- W4320483202 creator A5055831294 @default.
- W4320483202 creator A5056367377 @default.
- W4320483202 creator A5056951639 @default.
- W4320483202 creator A5057565228 @default.
- W4320483202 creator A5057885137 @default.
- W4320483202 creator A5059141298 @default.
- W4320483202 creator A5059314072 @default.
- W4320483202 creator A5060816944 @default.
- W4320483202 creator A5060969562 @default.
- W4320483202 creator A5063262748 @default.
- W4320483202 creator A5064374107 @default.
- W4320483202 creator A5066769987 @default.
- W4320483202 creator A5068910261 @default.
- W4320483202 creator A5070484447 @default.
- W4320483202 creator A5070907717 @default.
- W4320483202 creator A5073038301 @default.
- W4320483202 creator A5075771473 @default.
- W4320483202 creator A5076054848 @default.
- W4320483202 creator A5076087610 @default.
- W4320483202 creator A5078626524 @default.
- W4320483202 creator A5078860703 @default.
- W4320483202 creator A5079107294 @default.
- W4320483202 creator A5079189753 @default.
- W4320483202 creator A5079843750 @default.
- W4320483202 creator A5081342306 @default.
- W4320483202 creator A5081884947 @default.
- W4320483202 creator A5083525982 @default.
- W4320483202 creator A5083920423 @default.
- W4320483202 creator A5085499539 @default.
- W4320483202 creator A5085920118 @default.
- W4320483202 creator A5086212361 @default.
- W4320483202 creator A5086438162 @default.
- W4320483202 creator A5086640521 @default.